Successful treatment of a congenital extra-truncal vascular malformation by orally administered propranolol.

Abstract

Abstract The β-blocker propranolol has become a valuable and effective drug for the treatment of infantile hemangiomas. Its therapeutic action probably results from vasoconstriction, blocking of angiogenesis through effects on vascular endothelial growth factor and induction of apoptosis. It is reasonable to suggest that propranolol can also be used effectively in the treatment of other vascular abnormalities. This case report describes propranolol treatment of vascular malformations such as Klippel-Trénaunay syndrome or Parkes-Weber syndrome in adults.

• Authors: Claudia Pföhler, Eva Janssen, Arno Buecker, Thomas Vogt, Cornelia S L Müller
• Journal: The Journal of dermatological treatment (J Dermatolog Treat) Vol. 26 Issue 1 Pg. 59-62 (Feb 2015) ISSN: 1471-1753 [Electronic] England
• PMID: 24359542 (Publication Type: Case Reports, Journal Article)

Chemical References

• Adrenergic beta-Antagonists
• Vascular Endothelial Growth Factor A
• Propranolol

Topics

• Administration, Oral
• Adrenergic beta-Antagonists (administration & dosage, therapeutic use)
• Adult
• Female
• Humans
• Klippel-Trenaunay-Weber Syndrome (drug therapy, physiopathology)
• Propranolol (administration & dosage, therapeutic use)
• Treatment Outcome
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Vascular Malformations (drug therapy, physiopathology)